Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with type 2 diabetes.~* Have suboptimal glycemic control as evidenced by an HbA1c between 7.1% and 11.0% inclusive.~* Have a body mass index (BMI) of \>21 kg/m2 and \<35 kg/m2, inclusive.~* Have a history of stable body weight (not varying by \>5% for at least 90 days prior to study start).~* Have been treated with a stable dose regimen of Met, SU, TZD, Met plus SU, Met plus TZD, or SU plus TZD for at least 90 days prior to study start.~Exclusion Criteria:~* Have any contraindication for the OAD(s) that they use.~* Have a known allergy or hypersensitivity to exenatide BID, exenatide QW, or excipients contained in these agents.~* Have received chronic \>14 consecutive days) systemic glucocorticoid therapy by oral, intravenous (IV), or intramuscular (IM) route or intra-articular steroid injection within 4 weeks prior to study start or are regularly treated with potent, inhaled steroids that are known to have a high rate of systemic absorption.~* Have been treated with drugs that promote weight loss (for example, GLP-1 analogue, orlistat, sibutramine, phenylpropanolamine, or similar over-the-counter medications) within 90 days of study start.~* Have been treated for \>2 weeks with any of the following excluded medications within 90 days prior to study start:~  * Insulin~ * Dipeptidyl peptidase (DPP)-4 inhibitors (for example, sitagliptin or vildagliptin)~ * Pramlintide acetate~ * Drugs that directly affect gastrointestinal motility, including, but not limited to: Reglan® (metoclopramide), Propulsid® (cisapride), and chronic macrolide antibiotics.~* Have had prior exposure to exenatide~* Have previously completed or withdrawn from this study or any other study investigating exenatide BID or QW.~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.~* Are currently enrolled in any other clinical study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).